Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2025
0mins
Should l Buy ?
Merger Approval and Stock Split: Aerovate Therapeutics' stockholders have approved the merger with Jade Biosciences, including a reverse stock split of 1-for-35, which will reduce Aerovate's outstanding shares from approximately 30 million to about 0.8 million.
Post-Merger Trading and Dividend: The combined company's stock will begin trading under the name "Jade Biosciences, Inc." on April 29, with an aggregate cash dividend of $69.6 million payable to stockholders of record as of April 25.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
